Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.76 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.76 |
| ▸ | GPX4 | P36969 | 1/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 13/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8315964 | 0.90 | HDAC6 (0.65) | HDAC6HDAC1GPX4TRPV1TAAR1 | |
| SCHEMBL8252701 | 0.87 | HDAC6 (1.00) | HDAC6HDAC1GPX4TRPV1TAAR1 | |
| SCHEMBL18688569 | 0.87 | HDAC6 (0.77) | HDAC6HDAC1GPX4TRPV1TAAR1 | |
| SCHEMBL14924871 | 0.83 | HDAC1 (0.54) | HDAC6HDAC1GPX4TRPV1TAAR1 | |
| SCHEMBL12660615 | 0.83 | TRPV1 (0.55) | HDAC6HDAC1GPX4TRPV1TAAR1 | |
| SCHEMBL12660612 | 0.82 | HDAC1 (0.53) | HDAC6HDAC1GPX4TRPV1TAAR1 | |
| SCHEMBL12395382 | 0.81 | HDAC1 (0.51) | HDAC6HDAC1 | |
| SCHEMBL8320157 | 0.81 | HDAC6 (0.74) | HDAC6HDAC1GPX4TRPV1TAAR1 | |
| SCHEMBL12395383 | 0.81 | HDAC1 (0.50) | HDAC6HDAC1 | |
| SCHEMBL12660620 | 0.80 | HDAC1 (0.51) | HDAC6HDAC1GPX4TRPV1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291978-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291978-A1 | Enzyme Inhibitors | HAT1, NR2E1, NR2C2 | HDAC6 1058/4885HDAC1 9/4885GPX4 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.